Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study

Immune checkpoint inhibitors have greatly improved the prognoses of diverse advanced malignancies, including gastric and gastroesophageal junction (G/GEJ) cancer. However, the role of anti-programmed cell death protein-1 treatment in the neoadjuvant setting remains unclear. This phase 2 study aimed...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Wang, Ning Li, Jing Zhang, Ying Liu, Zhongqi Li, Nong Xu, Zhimin Ma, Yafei Zhang, Haiping Jiang, Xiongfei Yu, Mei Kong, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Yimin Lu, Kui Zhao, Ziran Li, Yisen Wang, Lisong Teng
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e003635.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/3/e003635.full

Similar Items